FGFR2 rearrangements are clinically actionable genetic alterations, as supported by evidence of clinical benefits with targeting the FGF/FGFR signaling pathways in patients with cholangiocarcinoma containing FGFR2 rearrangements.20 This evidence concerns the gene FGFR2 and cholangiocarcinoma.